Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.33 |
| ▸ | PPARG | P37231 | 2/20 | 0.33 |
| ▸ | PPARD | Q03181 | 2/20 | 0.33 |
| ▸ | PPARA | Q07869 | 2/20 | 0.33 |
| ▸ | MMP12 | P39900 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10212 | 1.00 | TDP1 (0.43) | TDP1SMN1; SMN2SLC22A6PARP1PARP10 | |
| SCHEMBL2580759 | 1.00 | TDP1 (0.43) | TDP1SMN1; SMN2SLC22A6PARP1PARP10 | |
| SCHEMBL11672388 | 0.97 | TDP1 (0.42) | TDP1SMN1; SMN2SLC22A6PARP1PARP10 | |
| SCHEMBL6742371 | 0.97 | TDP1 (0.42) | TDP1SMN1; SMN2SLC22A6PARP1PARP10 | |
| Ethylene Glycol SCHEMBL3731034 | 0.93 | TDP1 (0.39) | TDP1SMN1; SMN2SLC22A6PARP1PARP10 | |
| 1,4-Butanediol SCHEMBL3742951 | 0.89 | GPR84 (0.38) | TDP1SMN1; SMN2SLC22A6PARP1PARP10 | |
| Propylene Glycol SCHEMBL3741431 | 0.87 | TDP1 (0.40) | TDP1SMN1; SMN2SLC22A6PARP1PARP10 | |
| Succinic Acid SCHEMBL9642373 | 0.87 | FOLH1 (0.38) | TDP1SMN1; SMN2PARP1PARP10FOLH1 | |
| Di(Hydroxyethyl)Ether SCHEMBL3731296 | 0.85 | TSHR (0.39) | TDP1SMN1; SMN2SLC22A6PARP1PARP10 | |
| Tetraethylene Glycol SCHEMBL3742721 | 0.84 | MEN1 (0.41) | TDP1SMN1; SMN2PARP1PARP10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357301-A1 | HEXOSE DERIVATIVES, PREPARATION AND USES THEREOF | FACULDADE DE CIENCIAS DA UNIVERSIDADE DE LISBOA (PT) | 2023-11-09 | — | — | US | disclosed |
| US-9260459-B2 | 4,6-hexadecadiene-2,4-dicarboxylic acid derivative | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2016-02-16 | — | — | US | disclosed |
| US-20150183809-A1 | 4,6-HEXADECADIENE-2,4-DICARBOXYLIC ACID DERIVATIVE | KYOWA KIRIN CO., LTD. (JP) | 2015-07-02 | — | — | US | disclosed |
| EP-2566864-B1 | PYRIDAZINONES AS GPR119 AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2014-09-03 | — | — | EP | disclosed |
| US-8772323-B2 | Benzoxazole- and tetrahydrobenzoxazole-substituted pyridazinones as GPR119 agonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-08 | — | — | US | disclosed |
| US-20130172323-A1 | PYRIDAZINONES AS GPR119 AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-04 | — | — | US | disclosed |
| EP-2566864-A2 | PYRIDAZINONES AS GPR119 AGONISTS | Boehringer Ingelheim International GmbH (DE) | 2013-03-13 | — | — | EP | disclosed |
| WO-2011138427-A2 | PYRIDAZINONES AS GPR119 AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-10 | — | — | WO | disclosed |
| US-6953812-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK, INC. (DK) | 2005-10-11 | — | — | US | disclosed |
| US-20040024045-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2004-02-05 | — | — | US | disclosed |
| US-6562807-B2 | For prophylaxis and therapy of hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism, such as dyslipidemia, and obesity | NOVO NORDISK A/S (DK) | 2003-05-13 | — | — | US | disclosed |
| EP-1296942-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | Novo Nordisk A/S (DK) | 2003-04-02 | — | — | EP | disclosed |
| US-20020143186-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2002-10-03 | — | — | US | disclosed |
| WO-2002000612-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357301-A1 | HEXOSE DERIVATIVES, PREPARATION AND USES THEREOF | HK1, SLC5A1, HK2 | TDP1 4636/4885SMN1; SMN2 2954/4885SLC22A6 160/4885 |
| US-20130172323-A1 | PYRIDAZINONES AS GPR119 AGONISTS | GPR65, GPR119, GPR55 | TDP1 4382/4885SMN1; SMN2 3910/4885SLC22A6 1305/4885 |
| US-20150183809-A1 | 4,6-HEXADECADIENE-2,4-DICARBOXYLIC ACID DERIVATIVE | NR5A2, NR4A3, NR4A2 | TDP1 4653/4885SMN1; SMN2 3816/4885SLC22A6 423/4885 |
| US-20040024045-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | TDP1 3060/4885SMN1; SMN2 3973/4885SLC22A6 3366/4885 |
| US-20020143186-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | TDP1 3060/4885SMN1; SMN2 3973/4885SLC22A6 3366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.